Breathing cessation events that compose the apnea–hypopnea index are distinctively associated with the adverse outcomes in Alzheimer’s disease

Table 1 Baseline characteristics of the cohort

	Global
	n = 116
	n (%), mean (SD) or median [p₂₅;p₇₅]
*Sociodemographic data*
Sex, female	64 (55.2%)
Age, years	76.0 [72.0;80.0]
BMI, kg·m⁻²	27.7 [25.3;30.2]
Education, years	7.0 [7.0;7.0]
*Comorbidities*
Hypertension	73 (62.9%)
Diabetes mellitus	23 (19.8%)
Cardiopathy	25 (21.6%)
Depression	30 (25.9%)
Periodic limb movements	46 (44.7%)
*Alzheimer’s disease parameters*
Cognitive function
MMSE	23.0 [22.0;25.0]
Biomarkers levels
Aβ42, pg/ml	527 [415;643]
T-tau, pg/ml	464 [324;618]
P-tau, pg/ml	73.4 [52.3;94.4]
Genetic risk
ApoEε4 +	60 (53.1%)
*Sleep parameters*
Questionnaire
Epworth sleepiness scale	5.00 [3.00;8.00]
Polysomnography
Total sleep time, hours	4.57 [3.51;5.38]
Sleep efficiency, %	68.0 [53.7;78.2]
N1, %	12.1 [8.14;18.4]
N2, %	24.3 (11.3)
SWS, %	17.2 [8.27;24.5]
REM sleep, %	6.74 [2.48;11.2]
Latency to N1, minutes	21.0 [9.26;41.8]
Latency to REM, minutes	161 [99.6;250]
AHI	25.9 [15.1;48.5]

AHI apnea–hypopnea index, ApoEε4 + apolipoprotein E carrier, Aβ42, amyloid-beta protein, BMI body mass index, MMSE Mini-Mental State Examination, n number, p percentile, P-tau phosphorylated-tau, SD standard deviation, SWS slow-wave sleep, T-tau total-tau. Missings: biomarkers, 12; ApoEε4 + , 3

ISSN: 1758-9193